IL-1 in chronic arthritis, lessons from animal models

Drug Discovery Today: Disease Mechanisms

Volumn 3, Issue 2, 2006, Pages 169-175

  Joosten, Leo A B ^a   van den Berg, Wim B ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HYBRID PROTEIN; INTERLEUKIN 1; INTERLEUKIN 1 ANTIBODY; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL MODEL; ARTHROPATHY; AUTOIMMUNE DISEASE; CELL TYPE; CHRONIC ARTHRITIS; CHRONIC INFLAMMATION; HUMAN; INFLAMMATION; INFLAMMATORY DISEASE; NONHUMAN; PATHOGENESIS; REVIEW; RHEUMATOID ARTHRITIS;

EID: 33748507983     PISSN: 17406765     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ddmec.2006.06.004     Document Type: Review

References (37)

1. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 423 (2003) 356-361
2. Goronzy J.J., et al. Rheumatoid arthritis. Immunol. Rev. 204 (2005) 55-73
3. Arend W.P., et al. Inhibition of the production and effects of IL-1 and TNFα in RA. Arthritis Rheum. 38 (1995) 151-160
4. Roelofs M.F., et al. The expression of toll-like receptors 3 and 7 in rheumatoid arthritis synovium is increased and costimulation of toll-like receptors 3, 4, and 7/8 results in synergistic cytokine production by dendritic cells. Arthritis Rheum. 52 (2005) 2313-2322
5. Takeda K., et al. Toll-like receptors. Annu. Rev. Immunol. 21 (2003) 335-376
6. Dunne A., et al. The interleukin-1 receptor/Toll-like receptor superfamily: signal transduction during inflammation and host defense. Sci. STKE 25 (2003) 171
7. Beg A.A. Endogenous ligands of Toll-like receptors: implications for regulating inflammatory and immune responses. Trends Immunol. 23 (2002) 509-512
8. Schaefer L., et al. The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. J. Clin. Invest. 115 (2005) 2223-2233
9. Dinarello C.A. Biological basis for interleukin-1 in disease. Blood 87 (1996) 2095-2147
10. Braddock M., et al. Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention. Nat. Rev. Drug Discov. 3 (2004) 1-10
11. Dinarello C.A. Interleukin-1. Crit. Care Med. 33 (2005) S460-S462
12. Sims J.E., et al. A new nomenclature for IL-1-family genes. Trends Immunol. 22 (2001) 536-537
13. Dinarello C.A. Blocking IL-1 in systemic inflammation. J. Exp. Med. 201 (2005) 1355-1359
14. Andrei C., et al. The secretory route of the leaderless protein interleukin 1beta involves exocytosis of endolysome-related vesicles. Mol. Biol. Cell. 10 (1999) 1463-1475
15. Tschopp J.F., et al. NALPs: a novel protein family involved in inflammation. Nat. Rev. Mol. Cell Biol. 4 (2003) 95-104
16. Elssner A., et al. A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J. Immunol. 172 (2004) 4987-4994
17. Fantuzzi G., et al. Response to local inflammation of IL-1β-converting enzyme-deficient mice. J. Immunol. 158 (1997) 1818-1824
18. Coeshott C., et al. Converting enzyme-independent release of tumor necrosis factor α and IL-1β from a stimulated human monocytic cell line in the presensence of activated neutrophils or purified proteinase 3. Proc. Natl. Acad. Sci. U S A 96 (1999) 6261-6266
19. Irmler M., et al. Granzyme A is an interleukin-1β converting enzyme. J. Exp. Med. 181 (1995) 1917-1922
20. Burns K., et al. MyD88, an adaptor protein involved in interleukin-1 signaling. J. Biol. Chem. 273 (1998) 12203-12209
21. Janssens S., et al. Functional diversity and regulation of different interleukin-1 receptor associated kinases (IRAK) family members. Mol. Cell 11 (2003) 293-302
22. Van de Loo A.A.J., et al. Effects of murine recombinant IL-1 on synovial joint in mice: measurement of patellar cartilage metabolism and joint inflammation. Ann. Rheum. Dis. 49 (1990) 238-245
23. Santambrogio, L. et al. (1993) Antagonistic effects of endogenous and exogenous TGF-beta and TNF on auto-immune diseases in mice. Immunopharmacol. Immunotoxicol. 15, 461-478
24. Joosten L.A.B., et al. Accelerated onset of collagen-induced arthritis by remote inflammation. Clin. Exp. Immunol. 97 (1994) 204-211
25. Joosten L.A.B., et al. Anticytokine treatment of established type II collagen-induced arthritis in DBA/1 mice. A comparative study using anti-TNF alpha, anti-IL-1 alpha/beta, and IL-1Ra. Arthritis Rheum. 39 (1996) 797-809
26. Joosten L.A.B., et al. IL-1 alpha beta blockade prevents cartilage and bone destruction in murine type II collagen-induced arthritis, whereas TNF-alpha blockade only ameliorates joint inflammation. J. Immunol. 163 (1999) 5049-5055
27. Ku G., et al. IL-1β converting enzyme inhibition blocks progression of type II collagen induced arthritis in mice. Cytokine 8 (1996) 377-386
28. Saijo S., et al. Suppression of autoimmune arthritis in interleukin-1-deficient mice in which T cell activation is impaired due to low levels of CD40 ligand and OX40 expression on T cells. Arthritis Rheum. 46 (2002) 533-544
29. Mori L., et al. Attenuation of collagen-induced arthritis in 55-kD TNF receptor type I (TNFR1)-IgG1 treated and TNFR1-deficient mice. J. Immunol. 157 (1996) 3178-3182
30. Campbell I.K., et al. Severe inflammatory arthritis and lymphadenopathy on the absence of TNF. J. Clin. Invest. 107 (2001) 1519-1527
31. Lens J.W., et al. Flare-up of antigen induced arthritis in mice after challenge with intravenous antigen: kinetic of antigen in the circulation and localization of antigen in the arthritic and noninflamed joint. Arthritis Rheum. 29 (1986) 665-674
32. Van den Berg W.B., et al. Pathogenesis of joint damage in rheumatoid arthritis: evidence of a dominant role for interleukin-1. Baillieres Best Pract. Res. Clin. Rheumatol. 13 (1999) 577-597
33. Van den Berg W.B., et al. In vivo evidence for a key role of IL-1 in cartilage destruction in experimental arthritis. Agents Actions Suppl. 32 (1999) 159-163
34. Van den Berg W.B. Anti-cytokine therapy in chronic destructive arthritis. Arthritis Res. 3 (2001) 18-26
35. Wei S., et al. IL-1 mediates TNF-induced osteoclastogenesis. J. Clin. Invest. 115 (2005) 282-290
36. Miossec P. An update on the cytokine network in rheumatoid arthritis. Curr. Opin. Rheumatol. 16 (2004) 218-222
37. Dinarello C.A. Setting the cytokine trap for autoimmunity. Nat. Med. 9 (2003) 20-22